Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TARGET

Financiado

Cerrado

Targeting DNA repair pathways sparking anti cancer immunity

This project will test for the first time the hypothesis that therapeutic inactivation of DNA repair pathways in cancer cells can be exploited for patient benefit by reawakening an anti-tumor immune response. Genomic instability a... ver más

30/09/2026

UNITO

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-05

ERC-2020-ADG: ERC ADVANCED GRANT

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

UNITO

1.77M€ | Lider

MAPRO SISTEMAS DE ENSAYO

587.40K€ | Participante

COGENTECH SOCIETA BENEFIT SR...

N.D. | Participante

Proyectos interesantes

MIRIAM

Medical Technol...

Applied Physics

2M€ Cerrado

PID2019-104195GB-I00

Medical Technol...

Applied Physics

339K€ Cerrado

SAF2013-43255-P

Medical Technol...

Applied Physics

157K€ Cerrado

IMMR

Medical Technol...

Data Science

100K€ Cerrado

SAF2008-01596

Medical Technol...

Applied Physics

227K€ Cerrado

ReStreCa

Medical Technol...

Applied Physics

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 62 meses Fecha Inicio: 2021-07-05
Fecha Fin: 2026-09-30

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project will test for the first time the hypothesis that therapeutic inactivation of DNA repair pathways in cancer cells can be exploited for patient benefit by reawakening an anti-tumor immune response. Genomic instability and molecular heterogeneity, which occur in cancer cells with DNA repair deficiencies, fuel tumour progression and are associated with poor outcome. An exception is represented by Mismatch repair (MMR) deficient cancers as these tumours are exceedingly genetically heterogeneous but show favourable prognosis and remarkable response to immunotherapy. The molecular basis for the clinical outcome of MMR deficient cancers has long remained a mystery. Only recently it has become apparent that their biological properties are associated with increased levels of mutations, which unleash adaptive immunity and trigger immunosurveillance. We have reported that when MMR is impaired, cancers cells grow in immune-deficient mice but are unable to do so in immune competent animals. MMR inactivation increased the mutational burden and led to dynamic mutational profiles, resulting in persistent renewal of neoantigens and engagements of antigen-specific T cells. These data suggest an unprecedented high risk-high gain approach: the pharmacological blockade of proteins involved in DNA-repair as an anticancer therapy. This unconventional strategy builds on the concept that the immune system can identify and selectively target tumor cells carrying DNA alterations. Using in vitro and in vivo functional assays we will systematically assess whether and how inactivation of DNA repair genes provokes an immune response and restrict cancer growth. Notably, TARGET will discover and develop inhibitors of MMR and other DNA repair proteins that induce tumor immunity. The identification of DNA repair pathways which, when disabled, reawaken the immune system will provide transformative knowledge and could lead to the development of an entirely new class of anticancer drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores